Parallel Advisors, LLC Pro Qr Therapeutics N.V. Transaction History

Parallel Advisors, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 28, 2022	SELL	$0.9 - $8.39 $693 - $6,460	-770 Closed	0 $0
Q4 2021 Jan 20, 2022	BUY	$6.58 - $8.44 $4,948 - $6,346	752 Added 4177.78%	770 $6,000
Q3 2021 Nov 02, 2021	SELL	$5.16 - $8.47 $892 - $1,465	-173 Reduced 90.58%	18 $0
Q2 2021 Aug 06, 2021	BUY	$5.75 - $7.59 $1,098 - $1,449	191 New	191 $1,000
Q4 2020 Feb 02, 2021	SELL	$3.58 - $4.85 $1,102 - $1,493	-308 Closed	0 $0
Q3 2020 Oct 27, 2020	BUY	$4.79 - $6.3 $1,475 - $1,940	308 New	308 $1,000
Q2 2020 Jul 16, 2020	SELL	$4.5 - $6.53 $1,908 - $2,768	-424 Closed	0 $0
Q1 2020 Apr 27, 2020	BUY	$5.25 - $9.9 $1,044 - $1,970	199 Added 88.44%	424 $2,000
Q4 2019 Jan 30, 2020	BUY	$5.84 - $10.51 $1,314 - $2,364	225 New	225 $2,000
Q3 2019 Nov 01, 2019	SELL	$5.76 - $9.44 $1,935 - $3,171	-336 Closed	0 $0
Q2 2019 Aug 05, 2019	BUY	$9.1 - $15.55 $3,057 - $5,224	336 New	336 $3,000

17.4M

37.7K

21.3K

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $191M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Parallel Advisors, LLC with notifications on news.